Late and severe acute necrotizing pancreatitis in a patient with liraglutide

Therapie

Volumn 67, Issue 6, 2012, Pages 539-543

  Bourezane, Hayet ^a   Kastler, Bruno ^b,c   Kantelip, Jean Pierre ^a  

^a HÔPITAL SAINT JACQUES   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c I4S Laboratory   (France)

Author keywords

Liraglutide; Pancreatitis

Indexed keywords

LIRAGLUTIDE;

ACUTE HEMORRHAGIC PANCREATITIS; ARTICLE; PRIORITY JOURNAL;

EID: 84871515422     PISSN: 00405957     EISSN: 19585578     Source Type: Journal    
DOI: 10.2515/therapie/2012076     Document Type: Letter

References (21)

1. Gallwitz B. Glucagon-like Peptide-1 Analogues for type 2 diabetes mellitus. current and emerging agents. Drugs 2011; 71: 1675-88
2. Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like petide-1 agonist use. Ann Pharmacother 2010; 44: 904-9
3. Biour M, Daoud H, Ben Salem C. Pancréatotoxicité des médicaments. Seconde mise à jour du fichier bibliographique des atteintes pancréatiques et des médicaments responsables. Gastroenterol Clin Biol 2005; 29: 353-9
4. Lowenfels AB, Maisonneuve P, Sullivan T. The changing character of acute pancreatitis: epidemiology, etiology and prognosis. Curr Gastroenterol Rep 2009; 11: 97-103
5. Balani AR, Grendell JH. Drug-induced pancreatitis: incidence, management, and prevention. Drug Saf 2008; 31: 823-37
6. Chari ST, Vege SS. Etiology of acute pancreatitis. In: UpToDate. http://www.uptodate.com
7. Balthazar EJ, Robinson DL, Megibow AJ, et al. Acute pancreatitis: value of CT in establishing prognosis. Radiology 1990 Feb; 174(2): 331-6
8. Bégaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985; 40: 111-8
9. Noel R, Braun D, Patterson R, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32: 34-8
10. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150-6
11. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-78
12. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84-90
13. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-81
14. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224-30
15. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-55
16. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47
17. Lee PH, Stockton MD, Franks AS. Acute pancreatitis associated with liraglutide. Ann Pharmacother 2011; 45: e22
18. Steinberg WM. Comment: acute pancreatitis associated with liraglutide. Ann Pharmacother 2011; 45: 1169
19. Knezevich E, Crnic T, Kershaw S, et al. Liraglutide associated acute pancreatitis. Am J Health Syst Pharm. 2012 Mar 1; 69(5): 386-9
20. Frossard JL, Steer ML, Pastor CM. Acute pancreatitis, Lancet 2008; 371: 143-52
21. Toyoda-Akui M, Yokomori H, Kaneko F, et al. A case of Drug-induced hepatic injury associated with sitagliptin. Intern Med 2011; 50: 1015-20